Stoke Therapeutics (STOK) Payables (2018 - 2026)

Stoke Therapeutics' Payables history runs 9 years deep, the most recent figure standing at $6.8 million for Q1 2026.

• In Q1 2026, Payables rose 212.85% year-over-year to $6.8 million; the TTM figure through Mar 2026 stood at $6.8 million (up 212.85% YoY), while the FY2025 annual figure was $4.9 million, up 97.72% from the prior year.
• Payables for Q1 2026 stood at $6.8 million, up from $4.9 million in the prior quarter.
• The five-year high for Payables was $6.8 million in Q1 2026, with the low at $766000.0 in Q4 2022.
• The 5-year median for Payables is $3.1 million (2023), against an average of $3.3 million.
• Peak annual rise in Payables reached 274.04% in 2022, while the deepest fall reached 67.88% in 2022.
• Stoke Therapeutics' Payables stood at $766000.0 in 2022, then surged by 121.28% to $1.7 million in 2023, then surged by 47.37% to $2.5 million in 2024, then soared by 97.72% to $4.9 million in 2025, then surged by 38.47% to $6.8 million in 2026.
• Business Quant data shows STOK's Payables at $6.8 million in Q1 2026, $4.9 million in Q4 2025, and $5.9 million in Q3 2025.